Dabigatran Etexilate Mesylate and Sunmark Acid Reducer Ranitidine
Determining the interaction of Dabigatran Etexilate Mesylate and Sunmark Acid Reducer Ranitidine and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Talk to your doctor before using dabigatran if you are receiving raNITIdine for a gastrointestinal condition such as stomach ulcer or bleeding. Treatment with dabigatran may worsen your symptoms and increase the risk of bleeding. Contact your doctor if you experience potential signs and symptoms of bleeding such as dizziness; lightheadedness; red or black stools; coughing up or vomiting blood or blood clots; and abdominal pain. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Patients with gastrointestinal conditions may have an increased risk of gastrointestinal bleeding during concomitant treatment with dabigatran etexilate and proton pump inhibitors or H2 blockers. In addition, pantoprazole resulted in an approximately 30% decrease in dabigatran systemic exposure (AUC). Diminished clinical effect may occur, although no dosage adjustment is recommended for dabigatran etexilate. The pharmacokinetics of pantoprazole were not significantly altered by dabigatran. Pantoprazole and other proton pump inhibitors were also coadministered with dabigatran in clinical trials for the prevention of venous thromboembolic events after hip- or knee-replacement surgery, and no effects on bleeding or efficacy were observed. Ranitidine had no significant effects on the absorption of dabigatran.
MANAGEMENT: Patients should be monitored for signs of gastrointestinal bleeding and advised to promptly report any symptoms to their physician, such as abdominal pain, dizziness, lightheadedness, vomiting blood, anorexia, and/or black, tarry stools.
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Pradax (dabigatran)." Boehringer Ingelheim (Canada) Ltd, Burlington, IA.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim, Ridgefield, CT.
Generic Name: dabigatran
Brand name: Pradaxa
Synonyms: Dabigatran, Dabigatran Etexilate
Generic Name: ranitidine
Brand name: Zantac
Synonyms: Ranitidine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dabigatran Etexilate Mesylate-Sunmark All Day Allergy-D
- Dabigatran Etexilate Mesylate-Sunmark Anti-Diarrheal
- Dabigatran Etexilate Mesylate-Sunmark Anti-Diarrheal Tablet
- Dabigatran Etexilate Mesylate-SunMark ClearLax
- Dabigatran Etexilate Mesylate-Sunmark Hour Allergy Relief
- Dabigatran Etexilate Mesylate-Sunmark Ibuprofen Cold and Sinus
- Sunmark Acid Reducer Ranitidine-Dabrafenib
- Sunmark Acid Reducer Ranitidine-Dabrafenib Mesylate
- Sunmark Acid Reducer Ranitidine-Dacarbazine
- Sunmark Acid Reducer Ranitidine-Dacarbazine Intravenous, Injection
- Sunmark Acid Reducer Ranitidine-Daclatasvir
- Sunmark Acid Reducer Ranitidine-Daclatasvir Dihydrochloride